Krystal Biotech says its skin cancer treatment cut lesions by more than 80% in a rare disease trial.

KRYS · Krystal Biotech Inc.

The AI's read

The study gives Krystal an encouraging early sign for KB113, a possible treatment for people with repeated skin cancers. Tumors shrank across many lesions, and side effects were mild or moderate and went away. Still, only 3 people took part, and Krystal is discussing next steps with the FDA.